Table 2.
Distribution of somatic mutations in patients with OM-CMML, d-CMML, or p-CMML
| OM-CMML, n = 40, % | d-CMML, n = 37, % | p-CMML, n = 16, % | P (OM-CMML vs d-CMML) | P (d-CMML vs p-CMML) | P (OM-CMML vs p-CMML) | |
|---|---|---|---|---|---|---|
| ASXL1 | 17.5 | 13.5 | 62.5 | .757 | .001 | .003 |
| CALR | — | — | — | — | — | — |
| CBL | 2.5 | 16.2 | 31.3 | .051 | .275 | .006 |
| CSF3R | — | — | — | — | — | — |
| DNMT3A | 15 | 5.4 | 6.3 | .266 | .99 | .660 |
| ETV6 | 2.5 | 2.7 | — | .99 | .99 | .99 |
| EZH2 | 5 | — | 6.3 | .494 | .302 | .99 |
| IDH1 | 5 | — | — | .494 | — | .99 |
| IDH2 | 7.5 | 2.7 | 18.8 | .616 | .077 | .338 |
| JAK2 | 5 | 10.8 | 6.3 | .419 | .99 | .99 |
| KIT | — | — | — | — | — | — |
| KRAS | 2.5 | 10.8 | 12.5 | .189 | .99 | .193 |
| MPL | — | — | 6.3 | — | .302 | .286 |
| NRAS | 2.5 | 8.1 | 18.8 | .346 | .351 | .066 |
| RUNX1 | 12.5 | 10.8 | 6.3 | .99 | .99 | .662 |
| PRPF8 | — | 2.7 | — | .481 | .99 | — |
| SETBP1 | 5 | 2.7 | 6.3 | .99 | .517 | .99 |
| SF3B1 | 27.5 | 16.2 | 18.8 | .279 | .99 | .734 |
| SH2B3 | 5 | 2.7 | 12.5 | .99 | .213 | .570 |
| SRSF2 | 30 | 18.9 | 43.8 | .299 | .123 | .362 |
| STAG2 | 5 | — | — | .494 | — | .99 |
| TET2 | 72 | 73 | 81.3 | .99 | .731 | .734 |
| TP53 | 2.5 | 8.1 | 6.3 | .346 | .99 | .494 |
| U2AF1 | 2.5 | 2.7 | 12.5 | .99 | .213 | .193 |
| ZRSR2 | 20 | 10.8 | — | .352 | .303 | .089 |
| NRAS and/or KRAS | 2.5* | 16.2 | 31.3 | .051 | .275 | .006 |
| RAS pathway | 5 | 27 | 62.5 | .011 | .014 | <.001 |
Bold P values are statistically significant.
NRAS and/or KRAS, mutations in both genes or one of them; RAS pathway, mutations in CBL, NRAS, and/or KRAS genes.
*
One patient showed concurrent NRAS and KRAS mutations (Figure 1A).